The global gastrointestinal pathogen testing market was valued at US$ 4.0 Bn in 2022 and is projected to grow at a CAGR of 3.2% from 2023 to 2031, reaching more than US$ 5.2 Bn by the end of 2031. The market is witnessing steady expansion as healthcare systems worldwide increasingly prioritize rapid and accurate diagnostic solutions for infectious gastrointestinal diseases. Rising incidences of foodborne illnesses, bacterial and viral infections, and growing awareness regarding early disease detection are significantly driving the adoption of advanced gastrointestinal pathogen testing technologies across hospitals, diagnostic laboratories, and healthcare facilities.

Access key findings and insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85890

Market Overview

The gastrointestinal pathogen testing market plays a crucial role in modern healthcare diagnostics by enabling the detection of bacteria, viruses, and parasites responsible for gastrointestinal infections. The increasing burden of digestive disorders and infectious diseases, coupled with the need for timely diagnosis and treatment, is fueling demand for advanced testing solutions. Traditional diagnostic methods are gradually being replaced by molecular diagnostics and multiplex testing platforms that provide faster and more accurate results. Technological advancements in PCR-based diagnostics, next-generation sequencing, and automated testing systems are enhancing diagnostic efficiency and reducing turnaround times. Additionally, the growing focus on preventive healthcare and infection control measures is supporting the widespread adoption of gastrointestinal pathogen testing globally.

Market Size and Growth

Valued at US$ 4.0 Bn in 2022, the global gastrointestinal pathogen testing market is expected to surpass US$ 5.2 Bn by 2031, expanding at a CAGR of 3.2% during the forecast period. The market’s steady growth is driven by increasing healthcare expenditure, rising awareness about infectious disease management, and expanding access to advanced diagnostic services. The demand for rapid testing solutions surged significantly following heightened global attention toward infectious disease surveillance and public health preparedness. Furthermore, the growing prevalence of hospital-acquired infections and food contamination incidents is encouraging healthcare providers to invest in efficient pathogen testing systems. Emerging economies are also contributing to market growth through improvements in healthcare infrastructure and expanding diagnostic capabilities.

Market Segmentation

The gastrointestinal pathogen testing market can be segmented based on technology, pathogen type, end-user, and application. By technology, the market includes molecular diagnostics, immunoassays, culture-based methods, and others, with molecular diagnostics holding a dominant share due to their superior sensitivity and accuracy. In terms of pathogen type, the market is categorized into bacterial, viral, and parasitic infections, with bacterial pathogen testing accounting for a significant portion owing to the high prevalence of foodborne bacterial diseases. End-users include hospitals, diagnostic laboratories, academic research institutes, and point-of-care settings. Increasing adoption of multiplex assays capable of detecting multiple pathogens simultaneously is further transforming market dynamics and improving clinical efficiency.

Regional Analysis

Regionally, North America dominates the gastrointestinal pathogen testing market, supported by advanced healthcare infrastructure, high adoption of molecular diagnostic technologies, and strong awareness regarding infectious disease management. Europe also represents a substantial market share due to increasing investments in healthcare innovation and stringent food safety regulations. Asia-Pacific is anticipated to witness the fastest growth during the forecast period, driven by rising healthcare expenditure, growing population, and increasing prevalence of gastrointestinal infections in countries such as China and India. Meanwhile, Latin America and the Middle East & Africa are emerging markets, benefiting from improving healthcare access and increasing focus on disease surveillance and public health initiatives.

Competitive Landscape

The global gastrointestinal pathogen testing market is highly competitive, with leading companies focusing on technological innovation, product launches, strategic collaborations, and geographic expansion to strengthen their market presence. Prominent players operating in the market include bioMérieux SA, Becton, Dickinson, and Company (BD), QIAGEN, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Meridian Bioscience, Inc., Cepheid (Danaher Corporation), Laboratory Corporation of America Holdings, Illumina, Inc., DiaSorin S.p.A., Seegene, Inc., CerTest Biotec, S.L., Abbott, F. Hoffmann-La Roche Ltd., Genova Diagnostics, MicroGen DX, and Quidel Corporation. These companies are investing heavily in research and development activities to introduce innovative diagnostic solutions with enhanced speed, accuracy, and automation capabilities.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453